BeOne Medicines (ONC) Accounts Payables (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Accounts Payables data on file, last reported at $423.5 million in Q1 2026.

• Quarterly Accounts Payables rose 16.2% year-over-year to $423.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $423.5 million (up 16.2% YoY) and the FY2025 annual result came in at $479.0 million, up 18.28% from the prior year.
• Accounts Payables declined to $423.5 million in Q1 2026 per ONC's latest filing, from $479.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $479.0 million in Q4 2025 and bottomed at $234.4 million in Q2 2022.
• The 5-year median for Accounts Payables is $333.0 million (2024), against an average of $329.2 million.
• The widest annual swing landed in 2022, when Accounts Payables jumped 61.25%; it then decreased 10.04% in 2024.
• Tracing ONC's Accounts Payables over 5 years: stood at $294.8 million in 2022, then rose by 6.9% to $315.1 million in 2023, then increased by 28.53% to $405.0 million in 2024, then rose by 18.28% to $479.0 million in 2025, then declined by 11.58% to $423.5 million in 2026.
• Per Business Quant, the three latest ONC Accounts Payables figures stand at $423.5 million (Q1 2026), $479.0 million (Q4 2025), and $383.7 million (Q3 2025).

Peer Comparison